Multi-Cancer Early Detection: Understanding the Pathfinder Study and Clinical Implementation

Authors

Eric Klein, MD, Cleveland Clinic Lerner College of Medicine
Mylynda Massart, MD, PhD, University of Pittsburgh
Alexis Skoufalos, EdD, Thomas Jefferson UniversityFollow

Document Type

Presentation

Publication Date

12-8-2022

Comments

Presenters:

Eric Klein, MD
Emeritus Chairman, Glickman Urological & Kidney Institute
Professor of Surgery, Cleveland Clinic Lerner College of Medicine

Mylynda Massart, MD, PhD
Medical Director, UPMC Primary Care Precision Medicine Center
Assistant Professor, University of Pittsburgh

Moderator:

Alexis Skoufalos, EdD
Associate Professor
Associate Dean, Strategic Development
Program Director, DHSc in Population Health

Presentation: 59:03

Abstract

Multi-cancer early detection (MCED) assays represent a new paradigm in cancer screening with the potential to deliver on the promise of earlier detection of many cancers with a single test. This technology is quickly moving into the mainstream, which means more patients will be asking about it. In this webinar, we will explore the results of the Pathfinder Study, which evaluated the Galleri test, and we’ll hear how practitioners are implementing this cutting-edge technology into their practices.

Recommended Citation

Klein, MD, Eric; Massart, MD, PhD, Mylynda; and Skoufalos, EdD, Alexis, "Multi-Cancer Early Detection: Understanding the Pathfinder Study and Clinical Implementation" (2022). Innovation in Personalized Medicine & Population Health Speaker Series. Paper 4.
https://jdc.jefferson.edu/mcedspeakerseries/4

Language

English